TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE D-

NCT06589596: A Phase 1a/b Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of PRMT5 Inhibitor BGB-58067 Alone and in Combination With Anticancer Agents in Patients W

Sponsor: BeOne Medicines · Phase: PHASE1 · Area: ONCOLOGY · Target Enrollment: 695 pts

Competing Trials Overlap

8 Active Trials

Excess Burn Exposure

$6,597,360

Rescue Site Savings

+$4,366,824

Unlock Full NCT06589596 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06589596 Rescue Dossier →